LeMaitre Vascular (NASDAQ:LMAT) Announces Earnings Results, Misses Expectations By $0.04 EPS

Key Points

• LeMaitre Vascular reported quarterly EPS of $0.65, missing the $0.69 consensus estimate; revenue rose 11.3% year over year, while EPS fell from $0.75 a year earlier.
• Q3 organic sales grew 12%, and the company maintained its outlook for 11% full-year organic growth and adjusted EPS of $2.80, an 18% increase.
• Management cited RestoreFlow processing constraints and acquisition-related transition risks, while lowering full-year operating-margin guidance to 27% amid investment costs, inventory reserves, and foreign-exchange pressure.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) posted its earnings results on Wednesday. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.69 by ($0.04), FiscalAI reports. LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%. The company's quarterly revenue was up 11.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.75 EPS.

Here are the key takeaways from LeMaitre Vascular's conference call:

• Q3 organic sales grew 12%, driven by 7% pricing and 5% unit growth, with gains across products and regions. LeMaitre reiterated 11% full-year organic growth guidance and expects adjusted EPS to rise 18% to $2.80.
• The B. Braun acquisition adds vascular grafts and other devices with $9.4 million in 2025 sales, but the commercial transition is expected to take 18–24 months. LeMaitre warned of potential customer losses during the transition and expects to record only about $150,000 of related revenue in Q4.
• RestoreFlow revenue grew 34%, including 65% growth in cardiac tissue, but quality-control processing constraints are limiting how much product the company can release and sell. Management said the bottleneck may persist for a while as it adds resources to address it.
• Full-year operating-margin guidance is 27%, with the outlook reduced by about $1.4 million, reflecting the FAS-TIP inventory reserve, faster sales-force and infrastructure investment, RestoreFlow transfer costs, and foreign-exchange pressure. Q3 operating expenses rose 18% year over year.

LeMaitre Vascular Stock Up 9.1%

NASDAQ LMAT traded up $7.32 during trading on Wednesday, hitting $87.92. The stock had a trading volume of 514,878 shares, compared to its average volume of 271,336. The company has a market capitalization of $2.01 billion, a PE ratio of 29.63, a P/E/G ratio of 2.32 and a beta of 0.51. The company's 50-day moving average price is $81.38 and its two-hundred day moving average price is $94.16. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.96 and a current ratio of 16.31. LeMaitre Vascular has a 12 month low of $78.22 and a 12 month high of $118.01.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Wells Fargo & Company reduced their price target on shares of LeMaitre Vascular from $104.00 to $94.00 and set an "equal weight" rating for the company in a report on Wednesday, August 5th. Citigroup restated a "market outperform" rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Barrington Research cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Wednesday, August 5th. Weiss Ratings lowered shares of LeMaitre Vascular from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Friday, October 23rd. Finally, Wall Street Zen lowered shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, LeMaitre Vascular currently has an average rating of "Hold" and an average price target of $110.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.

Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.